Longevity Health Holdings Inc Stock Surges 115.50% to 150th in Trading Rankings Following $59 Million All-Stock Merger with THPlasma

On July 15, 2025, Longevity Health Holdings Inc. (XAGE) experienced a significant surge in its stock price, rising by 115.50%. The company's trading volume reached 6.54 billion, marking a 5160.14% increase from the previous day and placing it at the 150th position in the day's trading rankings.

Longevity Health Holdings Inc. announced a major all-stock merger with True Health Inc., the company behind THPlasma, a rapidly expanding player in the plasma collection industry. This merger, valued at $59 million with an additional $20 million contingent on performance goals, is expected to close by the end of 2025. The combined entity will continue to trade under the ticker XAGE on the Nasdaq, aiming to disrupt the longevity and healthcare sectors.

THPlasma, a key player in the merger, has shown remarkable growth, expanding from two plasma collection centers in New Jersey in 2024 to five across New Jersey and Pennsylvania in 2025. The company has secured guaranteed sales agreements worth $100 million annually and achieved cash profitability in the previous year. For 2025, THPlasma projects $10 million in revenue, $2 million in EBITDA, and $1 million in net income, with a forecasted 220% revenue jump to $32 million in 2026, along with $7 million in EBITDA and $4 million in net income.

This merger follows Longevity's earlier acquisitions of Carmell Therapeutics in 2023 and Elevai Skincare in January 2025, demonstrating its strategic focus on building a dominant presence in the longevity and healthy aging market. The company also canceled a planned deal with 20/20 BioLabs, indicating its commitment to the THPlasma partnership.

Investors are optimistic about the merger's potential to capitalize on the high demand for plasma-derived therapeutics, with the U.S. supplying over 60% of the global plasma. THPlasma's expansion plans and locked-in sales agreements position it to meet this demand, driving significant profits for the combined entity. Longevity's CEO, Rajiv Shukla, described the merger as a "significant inflection point" for shareholder value, while THPlasma's founder, George Chi, who will serve as Co-Chairman and CEO post-merger, called it a "transformative step" to accelerate growth.

However, the merger is not without risks. The stock's low float of 0.84 million shares can lead to significant price volatility, making it challenging to buy or sell without impacting the price. Additionally, the merger requires shareholder approval and regulatory clearance, with a target close in the fourth quarter of 2025. Any delays or failures to meet financial projections could negatively impact the stock price. The broader market volatility in the healthcare sector also poses risks, as regulatory changes or competition could affect the company's performance.

Despite these risks, the potential rewards are substantial. Longevity Health is establishing a niche in the growing longevity and healthy aging market, and the merger with THPlasma adds significant strength. The plasma collection sector is crucial for life-saving therapeutics, and THPlasma's guaranteed $100 million in annual sales and rapid growth plans through acquisitions and new centers could make XAGE a major player. The valuation of THPlasma at 2.5 times its projected 2026 revenue, including the earnout, is considered reasonable for a company with such growth potential. Longevity's stock was valued at $3.00 in the deal, a 12% premium over its July 11 close, reflecting confidence in the company's future.